As for the role of KRAS mutation in the effectiveness of anti-VEGF therapy in mCRC patients, a study has shown that tumor KRAS status could not predict treatment response or affect overall survival (OS) of mCRC patients receiving bevacizumab in combination with oxaliplatin-based regimens [20]. This evidence concerns the gene VEGFA and neoplasm.